TMOBy Calypso Research8 min read

Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Analysis

A Labored Growth at $12.2B for Thermo Fisher

Key Takeaways

Thermo Fisher Scientific Inc. (TMO) reported Q4 2025 earnings with revenue of $12.2B, representing a +7.2% year-over-year change. The stock moved -2.6% on earnings day.

The bull case: Thermo Fisher’s diversified portfolio, trusted-partner status in pharma/biotech, disciplined PPI-driven execution, and high-return M&A (including Clario and capacity expansion in pharma services) enable steady organic acceleration and high-single-digit EPS growth with meaningful upside if end markets normalize.

The bear case: Persistent macro and funding headwinds in academic/government and China, uncertainty around the pace of pharma/biotech spending recovery, integration and leverage risks from large digital and capacity acquisitions, and potential efficiency-driven dampening of wet-lab demand could cap organic growth near the low end of guidance and pressure returns.

Financial Highlights

  • Revenue: $12.2B (+7.2% YoY)
  • Gross Profit: $4.6B (38.0% margin, -1.2% YoY)
  • Operating Income: $2.3B (18.8% margin, -1.1% YoY)
  • Net Income: $2.0B
  • TTM Revenue: $44.6B

Stock Performance

  • Earnings Day Move: -2.6%
  • Year-to-Date: -12.8%
  • 1-Year Return: -3.6%
  • vs. S&P 500 (since earnings): +2.6%
  • vs. Nasdaq (since earnings): +4.3%

View live TMO data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Thermo Fisher Scientific Inc.'s Q4 2025 earnings call:

Sustainability and Drivers of the 2026 Organic Growth Acceleration (from ~2% to 3–4%)

Sentiment: Positive

"As a reminder, we had just under one point of pandemic runoff in our 2025 results. So, you know, adjusted for that, we roughly had 3% growth last year. And we're assuming that we're gonna be in the three to four range. And as Steven said, know, start with the assumptions, you know, around three." — Marc Casper
"The mid-point of our guidance assumes organic revenue growth is slightly above 3%. This is a step up from 2025. We think this appropriate to start at 3% at the beginning of the year. And as we through 2026, we can retire risk as we go and progress higher in the range." — Stephen Williamson

Pharma & Biotech Demand: Magnitude and Timing of a Spending Recovery

Sentiment: Positive

"So when I think about the tone of know, what we heard in the health care conference and and certainly in my meetings in Europe in January... consistent with what we've been hearing for a while, which is good confidence around the ability to navigate governments, and feel good about the, you know, things that have been agreed to. And excitement around their pipeline... and would say January in terms of what the sentiment is in our in our customer base, was quite positive." — Marc Casper
"What we expect over time or in this two year time frame is that just the absence of the negatives will start to allow for conditions to improve and and build within that range, but we don't wanna make any major changes until the markets start the year." — Marc Casper

LPBS / Pharma Services Capacity, Supply–Demand Tightness, and Growth Visibility

Sentiment: Positive

"When I think about industry demand capacity, really sterile fillfinish has been the area where there is heightened demand relative to industry capacity. It's part of the reason that we acquired the Sanofi site in New Jersey... so, the demand profile is good, and and our business is had a strong year and will continue to step up in growth over the next couple of years." — Marc Casper
"Embedded in the guidance is the assumption that Q1 organic revenue growth will be a couple of points lower than the full year 2026. This is largely driven by selling days and the expected phasing of our revenue in our pharma services business over course of 2026." — Stephen Williamson

Clinical Research / Accelerator & AI: Outsourcing Intensity and Impact of Digitalization

Sentiment: Mixed

"Authorizations have been far ahead of our revenue throughout the year and is showing a strong momentum in our competitive position... what it really is about is how do you shave a week off here, a month off there, how do you get waste out of the system, and ultimately, meaningfully bring the drugs to market more quickly or have insights that a drug is not performing well and, therefore, end a clinical trial more quickly." — Marc Casper
"When I think about how we are collaborating with OpenAI, really focused on the, you know, clinical research side of the thing the equation. Is how do you further shave time and cost out of the process? And have even more insights? And you know, that's gonna be a journey because it's a highly regulated industry, and we'll go on that journey with our customers." — Marc Casper

Analytical Instruments & Academic/Government Funding: Depth and Duration of Weakness

Sentiment: Mixed

"The analytical instruments team did a really good job in the fourth quarter. As you said, we had a more challenging comparison. And we were flat growth in the quarter. And we grew modestly in the full year... when I think about that dynamic, that's in a dynamic where you have pressures on academic and government funding. Also have pressures in China more broadly throughout the year." — Marc Casper
"Our assumption for academic and government embedded in our guidance is similar conditions to last year in aggregate... our assumption here is that there'll be a level of customer caution that will probably abate as the year goes down, but I I would still assume in our guidance it'll be a more cautious environment." — Marc Casper

Bull Case

Thermo Fisher’s diversified portfolio, trusted-partner status in pharma/biotech, disciplined PPI-driven execution, and high-return M&A (including Clario and capacity expansion in pharma services) enable steady organic acceleration and high-single-digit EPS growth with meaningful upside if end markets normalize.

Bear Case

Persistent macro and funding headwinds in academic/government and China, uncertainty around the pace of pharma/biotech spending recovery, integration and leverage risks from large digital and capacity acquisitions, and potential efficiency-driven dampening of wet-lab demand could cap organic growth near the low end of guidance and pressure returns.

Looking Ahead

Investors will be closely watching Thermo Fisher Scientific Inc.'s next quarterly report for continued execution, particularly around sustainability and Drivers of the 2026 Organic Growth Acceleration (from ~2% to 3–4%). With operating margins at 18.8%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Thermo Fisher Scientific Inc.'s revenue in Q4 2025?

Thermo Fisher Scientific Inc. reported Q4 2025 revenue of $12.2B, representing a +7.2% year-over-year change.

Did Thermo Fisher Scientific Inc. beat earnings expectations in Q4 2025?

The stock declined -2.6% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Thermo Fisher’s diversified portfolio, trusted-partner status in pharma/biotech, disciplined PPI-driven execution, and high-return M&A (including Clario and capacity expansion in pharma services) enable steady organic acceleration and high-single-digit EPS growth with meaningful upside if end markets normalize.

What is the bull case for TMO stock?

The bull case for TMO centers on: Thermo Fisher’s diversified portfolio, trusted-partner status in pharma/biotech, disciplined PPI-driven execution, and high-return M&A (including Clario and capacity expansion in pharma services) enable steady organic acceleration and high-single-digit EPS growth with meaningful upside if end markets normalize.

What is the bear case for TMO stock?

The bear case for TMO centers on: Persistent macro and funding headwinds in academic/government and China, uncertainty around the pace of pharma/biotech spending recovery, integration and leverage risks from large digital and capacity acquisitions, and potential efficiency-driven dampening of wet-lab demand could cap organic growth near the low end of guidance and pressure returns.

How has TMO stock performed since its Q4 2025 earnings?

TMO moved -2.6% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +2.6% since earnings. Year-to-date, the stock has returned -12.8%.

Browse all 400+ earnings reports →

Learn More

Analyze TMO in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Thermo Fisher Scientific Inc. and 400+ other stocks, explore the full platform.

Open TMO on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.